Want to see GOSS full AI Analyst Report?
GOSS Stock Chart & Stats
$0.45
-$0.10(-9.01%)
At close: 4:00 PM EST
$0.45
-$0.10(-9.01%)
Day’s Range― - ―
52-Week Range$0.14 - $3.87
Previous CloseN/A
Volume602.63K
Average Volume (3M)15.66M
Market Cap
$85.55M
Enterprise Value$203.89M
Total Cash (Recent Filing)$99.22M
Total Debt (Recent Filing)$202.93M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Aug 11, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding488,846,700
10 Day Avg. Volume15,280,242
30 Day Avg. Volume15,663,373
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-5.77
Price to Sales (P/S)14.62
P/FCF Ratio-4.13
Enterprise Value/Market Cap2.38
Enterprise Value/Revenue3.67
Enterprise Value/Gross Profit3.69
Enterprise Value/Ebitda-1.21
Forecast
1Y Price Target
$1.09Price Target Upside142.96% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.41
Revenue Forecast (FY)$36.42M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy Signal (PROSERA Phase III)A statistically significant 6MWD improvement (p=0.032) provides durable evidence of clinical activity for seralutinib. Persistent phase III efficacy signals support a credible regulatory submission and underpin potential commercial demand, reducing binary outcome volatility versus purely exploratory data.
Mechanistic Imaging Supports Clinical FindingsRobust CT FRI structural change correlated with 6MWD and biomarkers strengthens mechanistic validity of the drug's effect. These durable, objective imaging endpoints can supplement clinical outcomes in regulatory review and support labeling and payer discussions if validated.
Balance-sheet Restructuring To Extend RunwayA material reduction in convertible debt and maturity extension materially alters financing risk profile. If implemented, this structural change reduces near-term refinancing pressure, aligns capital timelines with regulatory milestones, and improves the company's ability to focus resources on NDA execution.
Bears Say
Weakened Balance Sheet And Negative EquityNegative equity and high nominal debt indicate cumulative losses have eroded the capital base, limiting financial flexibility. Over a multi-month horizon this constrains strategic options, increases dependence on dilutive financings, and raises vulnerability to adverse cash-flow scenarios.
Cash Burn And Short RunwaySubstantially negative operating cash flow and only months of runway create persistent financing risk. Near-term needs force tradeoffs between NDA execution and further dilution; inability to secure funding timely could disrupt regulatory timelines or commercialization preparedness.
Regulatory/execution Uncertainty From Primary Endpoint DesignMissing the prespecified alpha raises structural regulatory risk: FDA may view the result as underpowered versus protocol expectations, increasing reliance on secondary/mechanistic data and post‑approval commitments. This uncertainty affects approval probability and long-term commercial planning.
Gossamer Bio News
GOSS FAQ
What was Gossamer Bio’s price range in the past 12 months?
Gossamer Bio lowest stock price was $0.14 and its highest was $3.87 in the past 12 months.
What is Gossamer Bio’s market cap?
Gossamer Bio’s market cap is $85.55M.
When is Gossamer Bio’s upcoming earnings report date?
Gossamer Bio’s upcoming earnings report date is Aug 11, 2026 which is in 31 days.
How were Gossamer Bio’s earnings last quarter?
Gossamer Bio released its earnings results on May 18, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.166 by -$0.034.
Is Gossamer Bio overvalued?
According to Wall Street analysts Gossamer Bio’s price is currently Undervalued.
Does Gossamer Bio pay dividends?
Gossamer Bio does not currently pay dividends.
What is Gossamer Bio’s EPS estimate?
Gossamer Bio’s EPS estimate is -0.12.
How many shares outstanding does Gossamer Bio have?
Gossamer Bio has 488,846,700 shares outstanding.
What happened to Gossamer Bio’s price movement after its last earnings report?
Gossamer Bio reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.166. Following the earnings report the stock price went down -43.529%.
Which hedge fund is a major shareholder of Gossamer Bio?
Currently, no hedge funds are holding shares in GOSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gossamer Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.09 (142.96% Upside)
$1.09 (142.96% Upside)
Blogger Sentiment
Bullish
GOSS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 3.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-87.13%
12-Months-Change
Fundamentals
Return on Equity
174.85%
Trailing 12-Months
Asset Growth
-54.06%
Trailing 12-Months
Company Description
Gossamer Bio
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
GOSS Company Deck
GOSS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but constructive picture: clinically meaningful efficacy signals (including a traditional statistical threshold for 6MWD), supportive mechanistic CT FRI data across multiple lung compartments with clinical correlations, and decisive capital actions (debt reduction plan and cost containment) to preserve runway and focus on an NDA path. Counterbalancing these positives were key execution risks — the primary endpoint did not meet the prespecified alpha, a substantial workforce reduction was implemented, cash runway is short ($99M to Q1 2027), and the debt exchange depends on high noteholder participation and involves tradeoffs. Overall, the tone is cautious and pragmatic, emphasizing strengthened conviction in the program but acknowledging material near-term financial and regulatory risks.View all GOSS earnings summariesGOSS Stock 12 Month Forecast
Average Price Target
$1.09
▲(142.96% Upside)
Technical Analysis
Ownership Overview
1.86% Insiders
3.62% Mutual Funds
0.22% Other Institutional Investors
90.35% Public Companies and
Individual Investors